ALFRY.US Alfresa Holdings Corp Tokyo ADR
- Market cap
- USD 2.61B
- P/E
- 11.0x
- P/B
- 0.84x
- ROE
- 3.3%
- Dividend yield
- 1.43%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is ALFRY.US undervalued?
Graham numberALFRY.US trades 35.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alfresa Holdings Corp Tokyo ADR fundamental analysis
No fundamental analysis for Alfresa Holdings Corp Tokyo ADR yet.
Alfresa Holdings Corp Tokyo ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alfresa Holdings Corp Tokyo ADR
Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. The company operates through Wholesale of Prescription Drugs and Related Products, Wholesale of Self-Medication Products, Manufacturing of Pharmaceuticals and Related Products, and Pharmacy and Related Businesses segments. It is also involved in the oper…
Full company profileAlfresa Holdings Corp Tokyo ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alfresa Holdings Corp Tokyo ADR annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | 2.61T | 2.59T | 2.70T | 2.86T | 2.96T | 3.10T | 3.17T |
| Gross Profit | - | - | 183B | 187B | 192B | 206B | 214B | 218B | 212B |
| Operating Income | - | - | 27.9B | 29.1B | 30.1B | 38.5B | 38.1B | 36.2B | 26.1B |
| EBITDA | - | - | - | - | 52.0B | 57.4B | 54.6B | 77.4B | 28.6B |
| Net Income | - | - | 24.5B | 32.2B | 25.8B | 29.6B | 27.4B | 41.7B | 16.5B |
| EPS | - | - | 116 | 159 | 127 | 158 | 151 | 230 | 94 |
| Balance Sheet | |||||||||
| Total Assets | - | - | 1.32T | 1.30T | 1.34T | 1.45T | 1.44T | 1.51T | 1.54T |
| Total Liabilities | - | - | 827B | 832B | 852B | 968B | 958B | 999B | 1.04T |
| Shareholders' Equity | - | - | 490B | 472B | 488B | 480B | 482B | 507B | 494B |
| Cash & Short-term Investments | - | - | 170B | 180B | 160B | 214B | 177B | 193B | 184B |
| Cash Flow | |||||||||
| Operating Cash Flow | 46.9B | 33.8B | -21.2B | 36.5B | 13.1B | 86.4B | 5.64B | 38.6B | - |
| Capital Expenditure | 11.2B | 19.0B | 15.1B | 15.0B | 25.5B | 15.3B | 20.1B | 28.5B | 0.00 |
| Free Cash Flow | - | - | -39.4B | 19.6B | -12.4B | 71.1B | -14.5B | 10.0B | - |
| Ratios | |||||||||
| ROE | - | - | 5.0% | 6.8% | 5.3% | 6.2% | 5.7% | 8.2% | 3.3% |
| ROA | - | - | 1.9% | 2.5% | 1.9% | 2.0% | 1.9% | 2.8% | 1.1% |
| Net Profit Margin | - | - | 0.9% | 1.2% | 1.0% | 1.0% | 0.9% | 1.3% | 0.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Alfresa Holdings Corp Tokyo ADR dividends
- Dividend yield
- 1.43%
- Forward dividend
- 0.21 USD
- Payout ratio
- 28.8%
- Ex-dividend date
- Mar 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 12.0B | 66 | 28.8% |
| 2025 | JPY 12.6B | 69 | 45.8% |
| 2024 | JPY 12.2B | 66 | 41.4% |
| 2023 | JPY 11.1B | 55 | 43.2% |
| 2022 | JPY 11.4B | 56 | 35.5% |
| 2021 | USD 10.8B | 51 | 44.1% |
| 2020 | USD 10.4B | - | - |
| 2019 | USD 9.41B | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Alfresa Holdings Corp Tokyo ADR
Ownership data of Alfresa Holdings Corp Tokyo ADR is not available yet.
Alfresa Holdings Corp Tokyo ADR company profile
- Company name
- Alfresa Holdings Corp Tokyo ADR
- Ticker
- ALFRY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Medical Distribution
- Employees
- 12,525
- Fiscal year end
- March
- Address
- Ote Center Building, Chiyoda, Japan, 100-0004
- Phone
- 81 3 5219 5100
- Website
- alfresa.com
About Alfresa Holdings Corp Tokyo ADR
Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. The company operates through Wholesale of Prescription Drugs and Related Products, Wholesale of Self-Medication Products, Manufacturing of Pharmaceuticals and Related Products, and Pharmacy and Related Businesses segments. It is also involved in the operation of dispensing pharmacies and conducting related businesses; ethical pharmaceuticals wholesaling business; self-medication products wholesaling business; and other medical-related businesses. In addition, the company manufactures and markets active pharmaceutical ingredients; contract distribution services in hospitals; operation, maintenance, and development of information system; supply of cell raw materials; manufacturing of specific processed cells and regenerative medicine products; and engages in insurance agency, real estate management, and sales of daily necessities and consumables activities. Alfresa Holdings Corporation was incorporated in 2003 and is based in Chiyoda, Japan.
Alfresa Holdings Corp Tokyo ADR management
10- Mr. Ryuji ArakawaPresident & Representative Director · born 1963
- Mr. Yusuke FukujinExecutive VP & Representative Director · born 1976
- Mr. Shigeki OhashiDirector & Senior Managing Executive Officer · born 1965
- Mr. Toshiki TanakaDirector & Senior Managing Executive Officer · born 1963
- Miki OguchiSenior Executive Officer
- Mayumi JonaiSenior Executive Officer
- Mr. Kazuaki HanoExecutive Officer
- Mr. Soichi NemotoExecutive Officer
- Toshikazu UrakabeExecutive Officer
- Mr. Takashi SasakiExecutive Officer